Business
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Period Activity
− Achieved Fourth Quarter and Full Year 2019 ONPATTRO® (patisiran) Global Net Product Revenues of $55.8 Million and $166.4 Million, Respectively – − As of
About this update from Alnylam Pharmaceuticals, Inc.
[{"type":"text","content":"\n− Achieved Fourth Quarter and Full Year 2019 ONPATTRO® (patisiran) Global Net Product Revenues of $55.8 Million and $166.4 Million, Respectively –\n\n\n− As of Year-End 2019, Over 750 Patients Worldwide Receiving Commercial ONPATTRO, with Over 1,000 Total Patients Worldwide Being Treated with Patisiran –\n\n\n– Observed Strong Initial Demand for GIVLAARI™ (givosiran) in the U.S., with 13 Start Forms Received in First Six Weeks after FDA Approval –\n\n\n− Reported Third Positive 2019 Phase 3 Result with Lumasiran and Initiated Rolling Submission of New Drug Application (NDA) with U.S. Food and Drug Administration (FDA) –\n\n\n– Initiated HELIOS-B Phase 3 Study of Vutrisiran for the Treatment of Hereditary and Wild-Type ATTR Amyloidosis with Cardiomyopathy –\n\n\n– Maintained Strong Balance Sheet with Year-End Cash and Investments Balance of $1.55 Billion –\n\n\n− Provides 2020 ONPATTRO Revenue Guidance and Operating Expense Guidance –\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2019 and reviewed recent business highlights.\n\n\n“In 2019 we saw continued and steady growth of patients on ONPATTRO, and we expect growth to continue in 2020, driven by new patient finding, geographic expansion, and evidence-generating activities. We also believe that our ongoing APOLLO-B Phase 3 study, if positive, can potentially enable future label expansion for patisiran to treat the cardiomyopathy of hereditary and wild-type ATTR amyloidosis. With the early U.S. approval of GIVLAARI in the fourth quarter, Alnylam became a multi-product commercial company, and we are pleased with the strong initial interest from patients, physicians, and payers in the short period since the drug’s approval by the FDA,” said John Maraganore, Ph.D., Chief Executive Officer of Alnylam. “Also in the fourth quarter, we reported positive topline Phase 3 results with lumasiran, Alnylam’s third program in 2019 to achieve positive Phase 3 results, and we’ve initiated the rolling submission of an NDA, setting us up for a potential approval later this year. In addition, in 2020 we look forward to advancing additional late-stage programs closer to the market, namely vutrisiran – with the HEL...